Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rule 8.3- Skyepharma PLC

5 Dec 2005 15:08

HBM BioVentures (Cayman) Ltd05 December 2005 FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION Name of person dealing (Note 1) HBM BIOVENTURES (CAYMAN) LTD Company dealt in SKYEPHARMA PLC Class of relevant securityto which the dealings being disclosed relate (Note 2) ORDINARY SHARES Date of dealing 2 DECEMBER 2005 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) Long Short Number (%) Number (%) (1) Relevant securities 63,780,450 (8.46%)(2) Derivatives (other than options) NA (3) Options and agreements to purchase/sell NA Total 63,780,450 (8.46%) (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Class of relevant security: Long Short Number (%) Number (%) (1) Relevant securities (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total (c) Rights to subscribe (Note 3) Class of relevant security: Details 3. DEALINGS (Note 4) (a) Purchases and sales Purchase/sale Number of securities Price per unit (Note 5)PURCHASE (02.12.2005) 3,003,923 0.523042SALE N/A N/A (b) Derivatives transactions (other than options) Product name, Long/short Number of securities Price per unit e.g. CFD (Note 6) (Note 7) (Note 5) (c) Options transactions in respect of existing securities(i) Writing, selling, purchasing or varying Product Writing, Number of Exercise Type, e.g. Expiry Option moneyname, selling, securities price American, date paid/e.g. purchasing, to which European received call varying etc. the option etc. per unit option relates (Note 5) (Note 7) (ii) Exercising Product name, e.g. Number of securities Exercise price per unit call option (Note 5) (d) Other dealings (including new securities)(Note 4) Nature of transaction Details Price per unit (Note 8) (if applicable) (Note 5) 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the persondisclosing and any other person relating to the voting rights of any relevantsecurities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, this should bestated. Is a Supplemental Form 8 attached? (Note 9) NO Date of disclosure 05 DECEMBER 2005 Contact name JOHN ARNOLD Telephone number +1 345 946 8002 If a connected EFM, name of offeree/offeror with which connected NA If a connected EFM, state nature of connection (Note 10) NA Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Feb 20067:01 amRNSAppointment of New Chairman
1st Feb 20063:32 pmRNSRule 8.3- (Skyepharma Group)
1st Feb 20063:10 pmRNSRule 8.3- Skyepharma PLC
1st Feb 20062:20 pmRNSRule 8.3- SkyePharma plc
1st Feb 200611:46 amRNSEPT Disclosure
1st Feb 200611:32 amRNSRule 8.3-SkyePharma Plc
31st Jan 20062:54 pmRNSRule 8.3- (Skyepharma Group)
31st Jan 20062:46 pmRNSRule 8.3- Skyepharma PLC
31st Jan 200611:54 amRNSEPT Disclosure
31st Jan 20067:00 amRNSRule 8.3-Skyepharma PLC-Amend
30th Jan 20066:30 pmRNSRule 8.3- (Skyepharma Group)
30th Jan 20066:28 pmRNSRule 8.3- (Skyepharma Group)
30th Jan 200612:32 pmRNSRule 8.3- Skyepharma PLC
30th Jan 200611:18 amRNSRule 8.3-SkyePharma Plc
30th Jan 20067:01 amRNSFurther re call for EGM
27th Jan 20063:08 pmRNSRule 8.3- SkyePharma PLC
27th Jan 20061:19 pmRNSRule 8.3- Skyepharma PLC
27th Jan 200611:39 amRNSEPT Disclosure
26th Jan 20061:39 pmRNSHolding(s) in Company
26th Jan 20061:38 pmRNSRule 8.3- SkyePharma PLC
26th Jan 20061:35 pmRNSRule 8.3- Skyepharma PLC
26th Jan 200611:57 amRNSRule 8.3- Skyepharma Plc
25th Jan 200612:50 pmRNSRule 8.3- Skyepharma Plc
25th Jan 200612:04 pmRNSRule 8.3- SkyePharma PLC
25th Jan 200611:22 amRNSEPT Disclosure
24th Jan 20065:03 pmRNSEPT Disclosure - Amendment
24th Jan 200611:06 amRNSEPT Disclosure
23rd Jan 20064:50 pmRNSHolding(s) in Company
23rd Jan 200611:47 amRNSEPT Disclosure
23rd Jan 200611:45 amRNSEPT Disclosure
19th Jan 200612:13 pmRNSRule 8.3 - Skyepharma PLC
19th Jan 200611:42 amRNSRule 8.3- SkyePharma plc
19th Jan 200611:28 amRNSEPT Disclosure
18th Jan 20061:46 pmRNSRule 8.3 - Skyepharma PLC
18th Jan 200612:52 pmRNSRule 8.3- Skyepharma PLC
18th Jan 200611:17 amRNSEPT Disclosure
17th Jan 20063:09 pmRNSRule 8.3 - Skyepharma PLC
17th Jan 20062:57 pmRNSRule 8.3- Skyepharma PLC
17th Jan 200611:24 amRNSRule 8.3- SkyePharma plc
17th Jan 200611:16 amRNSRule 8.3- Skyepharma Plc
17th Jan 200611:08 amRNSRule 8.3- SkyePharma PLC
17th Jan 200611:02 amRNSEPT Disclosure
16th Jan 200611:01 amRNSNotice of Major Interest
13th Jan 20064:38 pmRNSRule 8.3 - Skyepharma PLC
13th Jan 20063:03 pmRNSRule 8.3- SkyePharma PLC
13th Jan 200612:49 pmRNSNotice of Major Interest
13th Jan 200611:14 amRNSRule 8.3- Skyepharma Plc
13th Jan 200611:03 amRNSEPT Disclosure
13th Jan 200610:29 amRNSRule 8.3- SkyePharma plc
12th Jan 20065:46 pmRNSRule 8.3- SkyePharma PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.